A 10-year-old Golden Retriever diagnosed with histiocytic sarcoma. Treatment began based on medical literature that suggested the tumor could bear KRAS and PTPN11 mutations, which are associated with response to the targeted drug cobimetinib, after an intial course of radiation therapy.
A SearchLight DNA™ test revealed absence of KRAS or PTPN11 mutations and presence instead of a mutation that suggested cobimetinib resistance. The treatment plan was switched to only radiation therapy and sirolimus.
Nine months after diagnosis, the patient was enjoying a high quality of life.